Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 3
2010 8
2011 3
2012 3
2013 6
2014 1
2015 3
2016 2
2017 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Cited In for PMID: 17470451

36 results

Results by year

Filters applied: . Clear all
Page 1
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. Leonard JP, et al. Ann Oncol. 2007 Jul;18(7):1216-23. doi: 10.1093/annonc/mdm114. Epub 2007 Apr 29. Ann Oncol. 2007. PMID: 17470451 Free article. Clinical Trial.
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL. Wang L, et al. Signal Transduct Target Ther. 2020 Mar 6;5(1):15. doi: 10.1038/s41392-020-0113-2. Signal Transduct Target Ther. 2020. PMID: 32296035 Free PMC article. Review.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP. Smith SM, et al. Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15. Lancet Haematol. 2017. PMID: 28314699 Free PMC article. Clinical Trial.
Novel Drugs in Follicular Lymphoma.
Anastasia A, Rossi G. Anastasia A, et al. Mediterr J Hematol Infect Dis. 2016 Nov 1;8(1):e2016061. doi: 10.4084/MJHID.2016.061. eCollection 2016. Mediterr J Hematol Infect Dis. 2016. PMID: 27872741 Free PMC article. Review.
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. Christian BA, et al. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7. Br J Haematol. 2015. PMID: 25847298 Free PMC article. Clinical Trial.
36 results